AI English summary of an SEC filing — figures as filed
Thermo Fisher Scientific TMOThermo Fisher announced the completion of its acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion in cash on September 2, 2025. The business, now Thermo Fisher's Filtration and Separation business, is part of the Life Sciences Solutions segment.
Key points
AI summaryThermo Fisher announced the completion of its acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion in cash on September 2, 2025. The business, now Thermo Fisher's Filtration and Separation business, is part of the Life Sciences Solutions segment.
The company said it mutually agreed with Solventum earlier this year to remove the Drinking Water Filtration business from the transaction, reducing the consideration payable at closing by $100 million. Solventum agreed to pay Thermo Fisher up to $75 million upon the sale by Solventum of its Drinking Water Filtration business or after an agreed upon 3-year period.
Thermo Fisher said the business serves Bioprocessing Filtration, Healthcare and Industrial Filtration, and Membranes, and is expected to generate approximately $750 million of full-year 2025 revenue.
The company expects the business to generate mid- to high-single digit organic growth and said the transaction is expected to be dilutive to adjusted earnings per share by $0.06 in the first year of ownership. It also expects to realize approximately $125 million of adjusted operating income from revenue and cost synergies by year 5 following the close.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Thermo Fisher Completes Acquisition of Solventum's Purification & Filtration Business
Thermo Fisher announced the completion of its acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion in cash on September 2, 2025. The business, now Thermo Fisher's Filtration and Separation business, is part of the Life Sciences Solutions segment.
Source · Based on the filing body and exhibits
Transaction Scope Adjusted; Drinking Water Filtration Excluded
The company said it mutually agreed with Solventum earlier this year to remove the Drinking Water Filtration business from the transaction, reducing the consideration payable at closing by $100 million. Solventum agreed to pay Thermo Fisher up to $75 million upon the sale by Solventum of its Drinking Water Filtration business or after an agreed upon 3-year period.
Source · Based on the filing body and exhibits
Annual Revenue Scale and Business Composition
Thermo Fisher said the business serves Bioprocessing Filtration, Healthcare and Industrial Filtration, and Membranes, and is expected to generate approximately $750 million of full-year 2025 revenue.
Source · Based on the filing body and exhibits
Company's Growth, EPS and Synergy Outlook
The company expects the business to generate mid- to high-single digit organic growth and said the transaction is expected to be dilutive to adjusted earnings per share by $0.06 in the first year of ownership. It also expects to realize approximately $125 million of adjusted operating income from revenue and cost synergies by year 5 following the close.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…